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Introduction: In hepatitis C virus (HCV)-related mixed cryoglobulinemia (MCG), the nonenveloped HCV core protein
(HCV-Cp) is a constituent of the characteristic cold-precipitating immune complexes (ICs). A possible correlation
between HCV-Cp, virologic, laboratory, and clinical parameters in both untreated MCG patients and those undergoing
specific treatment was explored.
Methods: HCV-Cp was quantified by a fully automated immune assay. Correlations between HCV-Cp and HCV RNA,
cryocrit, and virus genotype (gt) were investigated in 102 chronically HCV-infected MCG patients.
Results: HCV-Cp concentrations strongly correlated with HCV RNA levels in baseline samples. An average ratio of
1,425 IU and 12,850 IU HCV RNA per picogram HCV-Cp was estimated in HCV gt-1 and gt-2 patients, respectively. This
equation allowed us to estimate that, on average, HCV-Cp was associated with the viral genome in only 3.4% of the
former and in 35% of the latter group of patients. The direct relation between HCV-Cp and the cryocrit level suggests
that the protein directly influences the amount of cryoprecipitate. Although the therapy with rituximab (RTX) as a single
agent resulted in the enhancement of HCV-Cp levels, in patients treated with RTX in combination with a specific
antiviral therapy (pegylated interferon-α plus ribavirin), the prompt and effective clearance of HCV-Cp was documented.
Conclusions: Our data provide evidence that HCV-Cp has a direct effect on the cold-precipitation process in a virus
genotype-dependence in HCV-related MCG patients.Introduction
Chronic HCV infection is often associated with a large
spectrum of B-cell abnormalities [1,2], the most promin-
ent of which is the persistent production of circulating
immune complexes (ICs) [3-5]. In almost one third of
HCV-infected individuals, these ICs have cryoprecipitating
properties [6]. Within the clinical spectrum of chronic
HCV infection, mixed cryoglobulinemia (MCG), character-
ized by overt systemic vasculitis, nephropathy, and neur-
opathy, is a striking feature [7]. However, with or without
MCG, HCV infection is associated with an increased risk
of B-cell non-Hodgkin lymphoma (B-NHL) [8,9].
Restriction of both humoral and cellular immune re-
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reproduction in any medium, provided the orexpansions, has been detected in patients with MCG
[10-12]. Dominant cell clones contribute to the forma-
tion of intraportal follicle-like structures in chronically
HCV-infected livers [13]. Sequence analysis of the heavy-
chain complementarity-determining region-3 (CDR-3),
whether from circulating B-cell expanded clones or iso-
lated from liver follicle-like structures, demonstrated nu-
merous variations in this immunoglobulin gene segment,
supporting the notion that these cells are the result of an
antigen-driven response [14,15]. In addition, in a previ-
ous study, we determined that the restriction of B-cell V
gene use has a direct clinical impact, in that it is associ-
ated with high serum levels of rheumatoid factor (RF)
and extrahepatic disorders [13,16]. The mechanism(s) of
B-cell stimulation, however, is not known, nor has it been
established whether it is directly related to MCG. How-
ever, the answers to these questions are of interest, given
that only a subset of individuals with chronic HCV infec-
tion develops MCG and/or NHL. Furthermore, in MCG,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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specific activation markers have been described [17].
The cold-dependent insolubility of ICs in HCV-related
MCG is thought to result from a host reaction involving
primarily IgM molecules with RF activity and capable of
activating the complement cascade through the binding
of the globular domain of the C1q receptor (gC1q-R)
[18,19]. In certain viral infections, including HIV and
EBV, the responding naïve and memory B cells produce
polyreactive antibodies that exhibit bivalent heteroliga-
tion between a high-affinity combining site and a second
low-affinity molecular site located elsewhere on the
pathogen [20]. In MCG, conversely, HCV/IgG ICs are
thought to engage with an RF-like B-cell receptor to
stimulate B-cell expansion, which becomes autoreactive
through antigen-dependent somatic hypermutations [21].
This pathogenetic model, however, has yet to be confirmed
because the antigen(s) potentially involved in B-cell activa-
tion have not been identified.
The immunochemical structure of cold-precipitating
ICs is still poorly known, and the role of HCV in cryo-
precipitation has been shown only indirectly. We have
also not determined whether and to what extent HCV
envelope glycoproteins or defective interfering viral par-
ticles participate in cryoprecipitation. Nonetheless, in
a previous study, we showed that HCV nucleocapsid
(HCV-Cp), devoid of envelope proteins, is a constitutive
component of cryoglobulins [22] and is potentially able
to cause cryoglobulin-mediated tissue injury in vivo, via
gC1q-R [23]. In this model, C1q acts as a bridging mol-
ecule between circulating ICs containing HCV-Cp and
the vascular endothelium [18].
Tests for the quantitative determination of HCV-Cp
have been introduced to supplement PCR-based ana-
lysis of HCV RNA [24,25], to monitor antiviral therapy
[26,27], and to diagnose HCV infection in immunocom-
promised patients and in those undergoing hemodialysis
[28]. Recently, a fully automated, highly sensitive chemilu-
minescent immunoassay was developed to overcome the
shortcomings of conventional core assays [24,29]. In this
study, we made use of this advanced method to examine
the possible correlation between HCV-Cp, HCV RNA, and
viral genotypes (gts) in relation to cryoglobulin production.
The effect of B-cell depletion and specific antiviral therapy
on the levels of circulating and cold-precipitated HCV-Cp
was also explored.
Methods
Included in the study were 102 consecutive, unselected
patients with HCV-related MCG diagnosed between
2002 and 2012 at the Liver Unit, Department of Internal
Medicine and Clinical Oncology, University of Bari
Medical School. All patients had serum cryoglobulins
associated with clinical signs consisting of purpuricvasculitis, arthralgias, and, inconsistently, nephropathy
and/or neuropathy. The inclusion criteria were (a) posi-
tivity for anti-HCV antibodies and a positive PCR-based
assay to detect HCV RNA in serum; (b) detection of serum
cryoglobulins; (c) liver biopsy performed before enrollment;
(d) negativity for HBsAg and HIV antibodies; and (e) no
previous antiviral and/or immunosuppressive treatments.
Baseline evaluation included demographic data, medical
history, physical examination, evaluation of comorbidities,
and use of medications. The study was carried out accord-
ing to the principles of the Declaration of Helsinki and
Good Clinical Practice and was approved by the Ethical
Review Board of the University of Bari. Informed consent
for the collection and storage of their serum and peripheral
blood mononuclear cells (PBMCs) was obtained from all
subjects.
Laboratory parameters
Serum HCV antibodies were detected by second-/third-
generation enzyme-linked immunosorbent assays (Abbott
Lab, Chicago, IL, USA). Serum HCV RNA was determined
by RT-PCR (Roche Diagnostics System, Branchburg,
NJ, USA) and quantified with the Versant HCV RNA
quantitative 3.0 assay (Siemens Healthcare, Erlangen,
Germany). HCV genotyping was performed with INNO-
LiPA (Innogenetics NV, Ghent, Belgium). Liver biopsy
was carried out in all patients, and the histology speci-
mens were scored for grade and stage according to the
METAVIR score [30]. Neurologic assessment included
strength evaluation, electromyography, motor and sensory
nerve-conduction velocity, and short-latency somatosen-
sory evoked potentials. Cryoglobulins were isolated as
specified elsewhere [7]. Cryoprecipitates, diluted in 0.5M
NaCl, were fractionated with high-resolution gel electro-
phoresis, and monoclonal bands were identified by immu-
nofixation. Cryoglobulins were classified according to
Brouet et al. [31] as either type II, usually containing poly-
clonal IgG and a monoclonal IgM component, and type
III, containing polyclonal IgG and IgM.
HCV core protein determination
Cryopreserved serum samples, purified cryoglobulins, and
supernatants were tested for HCV-Cp by using Architect
HCV Ag (Abbott Diagnostics, Wiesbaden, Germany) and
retested for quantitative HCV RNA with the Cobas
Taqman assay (Roche Diagnostics GmbH, Mannheim,
Germany). The Architect HCV Ag assay is a fully auto-
mated, quantitative, chemiluminescent microparticle im-
munoassay for the detection of nonenveloped HCV-Cp
in HCV-infected sera [24]. One of the main feature of
this assay is the automated on-board pretreatment step
to lyse viral particles and to extract HCV-Cp by using solu-
tions containing urea, hydrochloric acid, and detergents. In
addition, the lysis step enables us to dissociate HCV-Cp
Figure 1 Time-related effect on the detection of nonenveloped
HCV-Cp in the cryoprecipitate samples over a period of 10 years
of storage.
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containing HCV-Cp particles released from cells undergo-
ing a necrotic process [26]. Total circulating nonenveloped
HCV-Cp, regardless of its biologic and molecular status,
is captured on the surface of paramagnetic microparti-
cles coated with three anti-core monoclonal antibodies
(moAbs) (that is, C11-3, C11-7, and AOT-3) recognizing
different epitopes of core protein and revealed with other
two acridium-labeled anti-core moAbs (that is, C11-9
and C11-14). The concentration of HCV-Cp in the speci-
men is determined by using a standard curve generated
by running six calibrators in duplicate. The cut-off value
of 0.06 pg recombinant C11 antigen (residues 1 to 160 of
HCV gt-2a)/ml (3.0 fM) was set by the manufacturer.
The kinetics of serum HCV-Cp was explored in
HCV-positive MCG patients under different therapeutic
schedules. In schedule A, 16 patients unresponsive to a
combination of pegylated interferon-α (pIFN-α) plus riba-
virin (RBV) were given four intravenous infusions of rituxi-
mab (RTX; Hoffmann-La Roche Ltd., Basel, Switzerland),
an anti-CD20+ chimeric monoclonal antibody, at a dose of
375 mg/m2 once a week over a period of 1 month. These
patients were described in a previous study [32].
IN schedule B, eight patients received RTX as in sched-
ule A, followed by pIFN-α once a week and RBV 800 to
1,200 mg/day according to body weight and viral gt.
The eight patients treated according to schedule C also
received RTX, pIFN-α, and RBV, as in schedule B, albeit
simultaneously.
Statistical analysis
Differences between data were expressed as median and
range. Spearman rank correlation coefficient (r) test was
used to evaluate the relations between variables. Changes
between measurements were assessed with nonparametric
tests including Friedman test and KS test. The Mann–
Whitney U test was used to compare HCV-gt-related
variables. For all statistical analyses, IBM SPSS statistics
version 19.0 was used. All reported P values were two-
sided; P < 0.05 was considered significant.
Results
All samples were analyzed for HCV-Cp twice with differ-
ent lots of reagents. Analytic evaluation of 102 chronic-
ally HCV-infected patients with MCG was carried out
by using five replicates of six cryoprecipitates with a low
cryocrit (2.1% ± 0.6%): three samples from gt-1 patients,
two from gt-2 patients, and one from a patient with gt-3.
An additional six cryoprecipitates with a high cryocrit
(11% ± 3.6%) were studied in parallel: three samples from
gt-1 patients, two from gt-2 patients, and one from a pa-
tient with gt-3. The coefficient of variation (CV) was
3.16% for the low-cryocrit group and 3.76% for the high-
cryocrit group.Reproducibility was defined by a control study per-
formed to verify the possible core protein shedding in the
cryoprecipitates during a long storage period. Five patients
who refused specific antiviral therapy and followed up for
more than 10 years with low doses of steroids were evalu-
ated. As reported in Figure 1, stable results were obtained
over the considered long period. Furthermore, six speci-
mens consisting of total serum and cold-precipitated sam-
ples of three HCV-positive MCG patients obtained in 2002
and three sera and cryoglobulins from three patients ob-
tained in 2012 were assayed in replicates of two at two sep-
arate times per day by using two lots of reagents. Results
showed a percentage CV of 6.5 and 4.6, respectively.
Specificity was tested by using the serum samples,
cryoprecipitates, and supernatants of 19 HCV-negative
MCG patients with the following clinical diagnoses:
“essential” MCG, not associated with any apparent dis-
ease (five women and one man, median age of 59 years,
ranging from 49 to 76, five with type II and one with
type III MCG); connective tissue disorders [systemic lupus
erythematosus (n = 3), dermatomyositis (n = 1), sclero-
derma (n = 1); four women and one man; median age of
60.5 years, ranging from 38 to 75 years, one with type II
and four with type III MCG]; B-NHL (one woman and
two men; median age of 52 years, ranging from 45 to
66 years, all with type II MCG); and chronic lymphocytic
leukemia (two women and three men; median age, 58 years
ranging from 51 to 78 years, all with type II MCG). Serum,
cryoprecipitate, and supernatant samples obtained from
each of these HCV-negative patients were consistently
negative for HCV-Cp. The linearity of the assay was veri-
fied in five serially diluted cryoprecipitates with HCV-Cp
levels >100 pg/ml. Linearity was maintained throughout
the entire dynamic range; the r coefficient ranged between
0.92 and 0.97.
Russi et al. Arthritis Research & Therapy 2014, 16:R73 Page 4 of 10
http://arthritis-research.com/content/16/2/R73The epidemiologic, virologic, laboratory, and clinical
characteristics are described in Table 1. The qualitative
results, determined by HCV-Cp and HCV RNA assays,
showed an agreement of 100%. All samples positive for
HCV-Cp were also positive for HCV RNA. HCV-Cp
was detected in all unfractionated serum specimens,
with a median levels of 18.3 pg/ml, ranging from 1.3 to
175.6 pg/ml; in all cryoprecipitates with a median of
18.5 pg/ml ranging from 0.1 to 105 pg/ml; and in all su-
pernatants with a median of 3.1 pg/ml, ranging from 0.2
to 91.3 pg/ml.
HCV gt-1 was detected in 51 patients (50%), HCV gt-2
in 49 (48.1%), and HCV gt-3 in the remaining two pa-
tients. The median age was 68 years, ranging from 44 to
80 years. Female gender greatly prevailed (78.4%), and
the median MCG disease duration was 7.5 years (1 to
26 years). Twenty-four (23.5%) patients had a history of
blood or blood-products transfusions. In the remainder,
the source of the HCV infection was unidentified. Over-
all, liver biopsy, performed in all patients at the time of
study inclusion, revealed a histologic picture compatible
with chronic active liver disease.
To evidence the in vivo phenotypic changes, peripheral
blood lymphocytes, obtained on the day of liver biopsy,
were analyzed with flow cytometry. Clinically, cutaneous
ulcers, peripheral neuropathy, and renal disease (including
glomerulonephritis and/or nephrotic syndrome) were con-
firmed in 40 (39.2%), 36 (35.3%), and 24 (23.5%) patients,
respectively.
Compared with gt-2 patients, those with gt-1 had sig-
nificantly lower HCV-Cp median concentrations, both
in unfractionated serum samples (15.6 pg/ml versus
24.1 pg/ml; P = 0.007) and in the supernatants (2.3 pg/ml
versus 4.6 pg/ml; P = 0.03). Conversely, HCV-Cp enrich-
ment in the cryoprecipitates was significantly higher
in gt-1 patients than in gt-2 patients (25.0 pg/ml versus
12.0 pg/ml, P = 0.04) (Figure 2). Differences in selective
enrichment of cold-precipitated HCV-Cp in gt-1 as com-
pared with gt-2 patients were also confirmed in samples
normalized for cryocrit (P < 0.002) and for cryoprecipita-
ble IgM (P = 0.009), whereas no difference was achieved
when samples were normalized for RF activity (P = 0.48)
and for protein concentration (P = 0.33).
These data suggested that the cold-dependent in-
solubility of HCV-Cp was gt-dependent, implying that
the dynamics of the cold-precipitation process may be
different between viral gts. As depicted in Figure 3,
individual HCV-Cp levels correlated well with those
of HCV RNA, both in the unfractionated serum sam-
ples evaluated in the complete series and as a function
of gts type. The r coefficient for the complete series
was 0.6290 (95% CI, 0.4919 to 0.7356: P < 0.0001)
(Figure 3A). In HCV gt-1 (Figure 3B) and gt-2 (Figure 3C)
patients, a positive statistically significant correlationwas determined (r = 0.5370 (95% CI, 0.3068 to 0.7079:
P < 0.0001) and 0.7807 (95% CI, 0.6362 to 0.8724: P <
0.0001), respectively].
Because all samples came from patients who were
treatment-naïve (that is, not treated with any antiviral or
immunosuppressive therapy, the HCV RNA-to-HCV-
Cp equivalence could be calculated. In the linear re-
gression analysis, HCV-Cp (log pg/ml) = 0.4791 × HCV
RNA (log IU/ml) – 1.5111 for gt-1 patients and 0.6794 ×
HCV RNA (log IU/ml) – 2.7916 for gt-2 patients. Thus,
1 pg of HCV-Cp per milliliter of serum sample was
equivalent to 1,425 IU and 12,850 IU of gt-1 and gt-2
HCV RNA/ml, respectively. For individual samples, this
correspondence varied substantially around the average,
ranging from 899 to 5,643 IU of gt-1 HCV RNA and
from 8,333 to 25,106 IU of gt-2 HCV RNA. This dis-
agreement in the ratio of HCV RNA and HCV-Cp in
HCV gt-1 and gt-2 patients likely reflects the different
amounts of core protein not associated with complete
viral genome, which may influence the cryoprecipitation
process.
We also asked whether cold-precipitated HCV-Cp
strictly correlated with the amount of cryoprecipitates
(Figure 4). When assessed in the complete series, a cor-
relation coefficient of 0.3180 (95% CI, 0.1239 to 0.4887:
P = 0.001) was determined (Figure 4A). The correlation
was stronger in gt-1 than in gt-2 patients (r = 0.4937
(95% CI, 0.2446 to 0.6817; P = 0.0002) and 0.3646 (95% CI,
0.0928 to 0.5858; P = 0.01)] (Figure 4B,C).
Figure 5 summarizes the results of a four-dose RTX
(schedule A) treatment plan in 16 MCG patients unre-
sponsive to combined pIFNα plus RBV antiviral therapy.
RTX therapy dramatically reduced cryoprecipitation,
resulting in a decrease in the mean cryocrit from 4.8% ±
3.2% at baseline to 1.9% ± 1.4% (P = 0.0002) at the end of
the last infusion. In step with the decrement in cryocrit
levels, HCV-Cp and HCV RNA concentrations were sig-
nificantly altered. HCV-Cp increased from 1.0 ± 0.18 log
pg/ml at baseline to 1.2 ± 0.12 log pg/ml (P = 0.02), ac-
companied by a simultaneous sustained increment in
HCV RNA, from 5.6 ± 0.2 log IU/ml to 5.9 ± 0.1 log IU/ml
(P = 0.004).
The dynamics of HCV-Cp in relation to therapeutic
schedules combining RTX, pIFNα, and RBV were ex-
plored (Figure 6). In schedule B, RTX was administered
once a week for 1 month, followed by pIFNα/RBV for
48 weeks. Schedule C consisted of the simultaneous ad-
ministration of RTX/pIFNα/RBV. In patients treated
with the former schedule, HCV-Cp levels increased in
parallel with RTX infusions but declined to unmeasur-
able levels during subsequent pIFNα/RBV administration
(Figure 6A). Conversely, in patients concomitantly treated
with RTX, pIFNα, and RBV, a rapid and vigorous decline
occurred in HCV-Cp (Figure 6B).
Table 1 Virologic, epidemiologic, histologic, laboratory,
and clinical characteristics of 102 patients with
HCV-related cryoglobulinemic vasculitis
Virology
Serum HCV RNA, n (%) 102 (100)
• Titer, log IU/ml, median (range) 5.64 (4.0-7.0)
Serum HCV core protein, n (%) 102 (100)
• Titer, pg/ml, median (range) 18.3 (1.3-175.6)
Cryoprecipitate core protein, n (%) 102 (100)
• Titer, pg/ml, median (range) 18.5 (0.1-105)
Supernatant core protein, n (%) 102 (100)
• Titer , pg/ml, median (range) 3.1 (0.2-91.3)
HCV Genotype, n (%)
• gt-1 51 (50)
• gt-2 49 (48.1)
• gt-3 2 (1.9)
Anti-HCV antibodies, n (%) 102 (100)
HBsAg, n (%) 0
Anti-HIV antibodies, n (%) 0
Epidemiology
Sex: M/F (ratio) 22/80 (0.27)
Age, years, median (range) 68 (44–80)
Presumed duration of cryoglobulinemic vasculitis,
years, median (range)
7.5 (1–26)
Blood/blood product transfusion, n (%) 24 (23.5)
Liver histology
Chronic active hepatitis, n (%) 92 (90.2)
Inflammation index, median (range) 3.1 (2.8-4.4)
Fibrosis index, median (range) 2.2 (1.6-3.8)
Cirrhosis, n (%) 10 (9.8)
Laboratory
Cryocrit, %, median (range) 5 (1–16)
Immunochemical type
• II, n (%) 96 (94.1)
• III, n (%) 6 (5.9)
Rheumatoid factor, (IU/ml, ≤20), median (range) 174 (20–4,470)
Immunoglobulins
• IgM (mg/dl, 40–230), median (range) 255 (17–1,273)
• IgG (mg/dl, 700–1,600), median (range) 1,180 (151–2,220)
Complement fraction
• C1q (mg/dl, 21–39), median (range) 36.5 (25–141)
• C3 (mg/dl, 90–180), median (range) 97.8 (4.1-228)
• C4 (mg/dl, 10–40), median (range) 3.15 (1–22)
ALT (IU/L, 30–65), median (range) 49 (19–265)
GGT (IU/L, 5–55), median (range) 57.5 (31–145)
Peripheral lymphocytogram
CD3 (%, 72 ± 10.2), median (range) 74 (36–89)
Table 1 Virologic, epidemiologic, histologic, laboratory,
and clinical characteristics of 102 patients with
HCV-related cryoglobulinemic vasculitis (Continued)
CD20 (%, 10.2 ± 5.4), median (range) 16 (5–73)
Symptoms
Palpable purpura, n (%) 85 (83.3)
Weakness, n (%) 61 (59.8)
Arthralgias/nonerosive arthritis, n (%) 66 (64.7)
Cutaneous ulcers, n (%) 40 (39.2)
Peripheral neuropathies, n (%) 36 (35.3)
Renal disease, n (%) 24 (23.5)
Membranoproliferative glomerulonephritis, n (%) 19 (79.2)
Nephrotic syndrome, n (%) 5 (20.8)
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The present data confirm and expand our previous re-
sults, which identified HCV-Cp as a constitutive compo-
nent of cryoglobulins [22]. By using a fully automated,
highly sensitive chemiluminescence immunoassay for the
determination of total HCV protein, we were able to
overcome the shortcomings of conventional core antigen
assays [24]. The intrinsic performance characteristics of
this novel method include its sensitivity and specificity,
even with thick and sticky cold-precipitating samples.
HCV core protein was detected in the blood of 100% of
the patients in our series and consistently precipitated by
cold separation. By contrast, in none of the samples from
patients with HCV-negative cryoglobulinemic vasculitis
did the assay yield positive results.
Given the potential impact on the clinical and biologic
features of MCG, several studies have focused on the
quantitative relation between HCV-Cp and HCV RNAFigure 2 Comparison of HCV-Cp levels in unfractionated sera,
cryoprecipitates, and supernatants in 51 MCG patients infected
with HCV gt-1 and 49 MCG patients infected with HCV gt- 2.
Figure 3 Correlation between HCV-Cp and HCV RNA concentrations in all unfractionated serum samples (A) and in those grouped
according to viral genotype 1 (B) and genotype 2 (C). Data on the axes are log scaled.
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culating HCV-Cp and serum HCV RNA levels in MCG
patients, suggesting that the HCV-Cp concentration re-
flects viral replication. However, HCV-Cp and HCV RNA
titers in serum are neither directly equivalent nor simply
stoichiometrically related; thus, changes in either one are
likely indicative of a change in biologic status, as reported
for the HCV-infected general population [35]. RNA-free
Cp-containing structures may be present in serum; how-
ever, although the serum level of HCV-Cp mirrors its
intrahepatic concentration, it cannot be strictly considered
a direct marker of viral replication [36].
Because the structure of HCV particles is not precisely
known, the ratio of HCV RNA to Cp cannot be accur-
ately determined. It has been estimated that 1 pg of
HCV-Cp contains 130,000 HCV genome molecules [37].
In our study, HCV RNA in gt-1 and gt-2 MCG patients
never exceeded 6,000 IU and 26,000 IU per picogram
Cp, respectively, indicating a remarkable differences be-
tween viral gts. Because each virion presumably containsFigure 4 Correlation between HCV-Cp levels and cryocrit values in all
(B) and genotype 2 (C).a single genome molecule and a constant number of
capsomers [38], our results point to different amounts of
Cp associated with HCV RNA-free structures among
HCV gts. These gt-dependent differences support the es-
timated average association of only 3.4% (gt-1) and 35%
(gt-2) of the total pool of Cp with the viral genome. Thus,
in MCG patients, an overproduction of HCV-Cp by in-
fected hepatocytes and the release of the protein as
RNA-free core structures into the blood, where it acts as
a decoy for the immune system, can be envisaged as the
major mechanism underlying the formation of ICs with
cryoprecipitating properties.
However, the reasons for the difference in HCV-Cp
concentrations between HCV gts remains unclear, as
already reported [39,40]. Although it could be speculated
that the detection of HCV-Cp in MCG patients primar-
ily reflects core antigen masked within antigen-antibody
ICs, the analytic process is expected to dissociate these
complexes. Nonetheless, supporting this assumption is
the significantly greater enrichment in gt-1 patients ofpatients (A) and in those grouped according to viral genotype 1
Figure 5 Effect of four-dose rituximab treatment on HCV RNA,
HCV-Cp, and cryocrit in 16 patients with HCV-related MCG who
were unresponsive to a combination of pegylated interferon-α
and ribavirin.
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showing RF activity and HCV-Cp, as in this form of
MCG, the RNA-to-Cp ratio is higher. It is well known
that the genetic variability of HCV affects the metabolism
of infected liver cells and influences the outcome of in-
fection [41]. In addition, the RNA chaperone activity of
core protein includes genomic RNA dimerization, which
may constitute the regulatory switch determining transla-
tion/replication versus replication/packaging of viral
RNA [42]. It has also been reported that the altered pro-
teins in the different gts are similar, but a single amino
acid change could modulate the interactions of core pro-
tein with virus and/or host proteins, strongly influencing
its stability. Many of these polymorphisms may, in turn,
predict RNA structures and could differentially regulateFigure 6 HCV-Cp concentrations under treatment schedules comprisi
(A) and the simultaneous administration of these drugs (B).the metabolic processes that give rise to different disease
conditions [43,44]. A single substitution within the HCV
core-antigen sequence (A48T) reduces the sensitivity of a
commonly used chemiluminescence enzyme-linked im-
mune assay [43]. Despite the genetic variations between
gts, a key viral sequence may help to predict Cp levels in
MCG.
The host component interactions that explain the
higher propensity to cold precipitation in gt-1 patients sup-
port the differential regulation of HCV-Cp transcription
and translation within the two major HCV gts in MCG pa-
tients. If confirmed, it would distinguish individuals with
HCV-related MCG from the HCV-infected general popu-
lation, in which the viral genotype has no significant effect
on the RNA-to-HCV Cp ratio [25,26,35,39,40,45-47].
By using the Architect assay to measure HCV-Cp in
cryoprecipitates, we obtained evidence for a direct rela-
tion between the levels of cold-precipitated protein and
the cryocrit, and thus were able to establish that the Cp
concentration directly influences the amount of cold-
precipitation. Again, a viral gt dependence could be dem-
onstrated, in that the correlation was higher in gt-1 than in
gt-2 patients. The underlying explanation for these findings
is as yet unknown, but it may be that Cp does not increase
in parallel with the release of HCV RNA and that the kin-
etics of ICs formation as well as the clearance of ICs from
the circulation differ among the HCV gts. However, despite
discrepancies in HCV core dynamics, organ-related dam-
age, including nephropathies and neuropathies, is the same
in MCG gt-1 and gt-2 patients, suggesting that factors
other than Cp adversely affect clinical outcome.
Clinical studies have established HCV-Cp thresholds
for use in tailoring the treatment of chronic HCV infec-
tion with combined pIFN-α/RBV. Quantitative measure-
ment of total HCV-Cp may also be used during and after
treatment to assess the response to therapy [27,37,40,48].
The assessment of HCV-Cp kinetics during treatment was
recently shown to aid in understanding the mechanisms of
action of antiviral drugs [49]. However, antiviral treatmentng rituximab followed by pegylated interferon-α and ribavirin
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for the persistent production of cryoglobulins, because
cryoglobulinemic vasculitis persisted in one series of pa-
tients treated successfully for HCV infection [50] and who
relapsed, despite the achievement of a biologic response by
another group of treated patients [51].
The introduction of RTX, a chimeric monoclonal anti-
body directed to CD20 antigen, has undoubtedly improved
the therapeutic results in MCG by inducing in vivo B-cell
depletion [32,52]. We previously demonstrated that RTX
administration causes a substantial reduction in the cryo-
crit percentage, but also a significant increment of HCV
RNA [32]. This was also observed in the RTX-treated pa-
tients in the present study, based on measurements of
HCV-Cp levels. In this group, despite the cryocrit decre-
ment, a prompt increase in serum HCV-Cp occurred.
Enhanced core antigenemia and a parallel increase in
viremia in the presence of RTX treatment are likely the
result of infectious HCV particles released from lysed B
cells, as demonstrated elsewhere [53]. They are, indeed,
potentially harmful features that may lead to further acti-
vation of the immune system, resulting in clonal expan-
sions of B cells with remarkable stability and functional
as well as biologic autonomy. By contrast, a prompt clin-
ical response, accompanied by the effective clearance of
HCV-Cp and HCV RNA, was induced by treating pa-
tients simultaneously with RTX and pIFN-α/RBV.
Conclusions
Our findings demonstrate that (a) HCV-Cp levels are
closely related to the amount of cryoprecipitate; (b) HCV-
Cp cryoprecipitation is gt-dependent; (c) the production of
HCV-Cp associated with HCV RNA-free structures is
considerably greater in gt-1 rather than gt-2 MCG pa-
tients; (d) a significant increment of HCV-Cp occurs after
RTX-induced B-cell depletion. Nevertheless, the impli-
cations of these results on the structural and clinical
features of MCG await further studies in a larger co-
hort of patients, including more of type III MCG, that
in almost 2% of cases can spontaneously switch from
type II MCG with significant changes of clinical mani-
festations, normalization of C4 serum levels, and lowering
of RF activity, as recently demonstrated by our group in a
15-year prospective study [54].
In principle, given the strong relation between HCV-
Cp and cold-precipitated proteins, these findings prove
that HCV-Cp determination can be favorably applied as
a supplemental test in monitoring the variegate clinical
features of MCG vasculitis as well as response to antiviral
treatment of these patients. It can be assumed that high
production of HCV RNA-free core structures may contrib-
ute to the dysregulation of adaptive immune response,
resulting in increased risk of uncontrolled lymphoprolifera-
tion in these patients [16].Abbreviations
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